Effect of Cabergoline on biochemical and anthropometric parameters of patient with Impaired Glucose metabolism (Impaired Fasting Glucose/Impaired Glucose Tolerance)

Effect of Cabergoline Vs placebo on HbA1C, HOMA-IR, HOMA-Beta, FPG, anthropometric parameters in patient with Impaired fasting glucose/Impaired glucose tolerance.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12613001121752

Enrollment

Registered

2013-10-08

Start date

2013-07-01

Completion date

2013-10-30

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Impaired Glucose metabolism has no treatment and only life style modification could stop progression of this condition to diabetes, so we want to try effect of cabergoline in this condition to alleviate metabolic impairment and progression to diabetes.

Interventions

addition of Cabergoline 0.5 mg oral tabletes twice weekly for 4 month or placebo in patients with prediabetes receiving a balanced diet, to to measure patient compliance to Cabergoline, tablet returned counted at the final visit, in addition to comparing thr prolactin level of every patient.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Healthy volunteers

Inclusion criteria

Fasting Plasma Glucose (FPG): 100-110 mg/dL or/and 2 hour Plasma Glucose after Oral Glucose Tolerance Test (2hPG): 140-199 mg/dL.

Exclusion criteria

1) severe hepatic failure (Child-Pugh scores of 10 or higher) 2) history of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders; increased risk of pleural effusion/pulmonary fibrosis 3) hypersensitivity to ergot derivatives 4) uncontrolled hypertension 5) Diabetes 6) Pregnant Women 7) Lactating Women 8) Major psychiatric disorders 9) Recieving Medication effect prolactin secretion 10) Bulimia or/and anorexia nervosa

Outcome results